KIMBERLY LAVENDER: Open Payments
NPI 1619261930 · KIRKLAND, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$538 in 29 payments from 9 companies in 2025. Trend: 2023 $643 · 2024 $454 · 2025 $538
Food & beverage: $538
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $195 |
| Janssen Biotech, Inc. | 4 | $93 |
| GENZYME CORPORATION | 3 | $58 |
| Phathom Pharmaceuticals, Inc. | 4 | $57 |
| Madrigal Pharmaceuticals | 2 | $49 |
| Aimmune Therapeutics, Inc. | 1 | $29 |
| Novo Nordisk Inc | 1 | $23 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
Products named: RINVOQ, TREMFYA, DUPIXENT, VOQUEZNA, MAVYRET, REZDIFFRA, VOWST, Wegovy.
Industry payments across WA — which companies pay providers there.
